Inhibition of experimental abdominal aortic aneurysm progression by nifedipine

International Journal of Molecular Medicine

Volumn 21, Issue 2, 2008, Pages 239-244

  Tomita, Naruya ^a,b   Yamasaki, Keita ^a   Izawa, Keiko ^a   Kunugiza, Yasuo ^a   Osako, Mariana K ^a   Ogihara, Toshio ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Abdominal aortic aneurysm; Nifedipine

Indexed keywords

ANGIOTENSIN II; ELASTASE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NIFEDIPINE;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; AORTA FLOW; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; HEART RATE; HUMAN; HUMAN CELL; MALE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 38949140498     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.21.2.239     Document Type: Article

References (56)

1. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, Barone GW, Bandyk D, Moneta GL and Makhoul RG: The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 160: 1425-1430, 2000.
2. Lederle FA, Johnson GR and Wilson SE: Abdominal aortic aneurysm in women. J Vasc Surg 34: 122-126, 2001.
3. Darling RC, Messina CR, Brewster DC and Ottinger LW: Autopsy study of unoperated abdominal aortic aneurysm: a population-based study. J Vasc Surg 18: 74-80, 1993.
4. Van der Vliet JA and Boll APM: Abdominal aortic aneurysm (seminar). Lancet 349: 863-866, 1997.
5. Collin J: The epidemiology of abdominal aortic aneurysm. Br J Hosp Med 40: 65-68, 1998.
6. Wilmink A and Quick C: Epidemiology and potential for prevention of abdominal aortic aneurysm. Br J Surg 85: 155-162, 1998.
7. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM and Powell JT: Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 15: 1145-1151, 1995.
8. Curci JA, Liao S, Hoffman MD, Shapiro SD and Thompson RW: Expression and localization of macrophage elastase (matrix metalloproteinases-12) in abodominal aortic aneurysms. J Clin Invest 102: 1900-2000, 1998.
9. Rijbroek A, Moll FL, van Dijk HA, Meijer R and Jansen JW: Inflammation of the abdominal aortic aneurysm wall. Eur J Vasc Surg 8: 41-46, 1994.
10. Koch AE, Haines GK, Rizzo R, Radoservich JA, Pope RM, Robinson PG and Pearce WH: Human abdominal aortic aneurysms; analysis suggesting an immune-mediated response. Am J Pathol 137: 1199-1213, 1990.
11. Brophy CM, Marks WH, Reilly JM and Tilson MD: Decreased tissue inhibitor of metalloproteinases (TIMP) in abdominal aortic aneurysm tissue: a preliminary report. J Vasc Surg 50: 653-657, 1991.
12. Shark PK: Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation 96: 2115-2117, 1997.
13. Newman KM, Jean-Claude J, Li H, Scholes JV, Ogata Y, Nagase H and Tilson MD: Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg 20: 814-820, 1994.
14. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP, Welgus HG and Parks WC: Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 96: 318-326, 1995.
15. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC and Thompson RW: Doxycycline inhibition of aneurismal degradation in an elastase-induced rat model of abdominal aortic aneurysm: prevention of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 23: 336-346, 1996.
16. Knox JB, Sukhova GK, Whittemore AD and Libby P: Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 95: 205-212, 1997.
17. McMillan WD, Tamarina NA, Cipollone M, Johnson DA, Parker MA and Pearce WH: Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 96: 2228-2232, 1997.
18. Moore G, Liao S, Curci JA, Starcher BC, Martin RL, Hendricks RT, Chen JJ and Thompson RW: Suppression of exprimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). J Vasc Surg 29: 522-532, 1999.
19. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM and Thompson RW: Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysm. J Clin Invest 105: 1641-1649, 2000.
20. Boyle JR, McDermott E, Crowther M, Wills AD, Bell PR and Thompson MM: Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurismal disease. J Vasc Surg 27: 354-361, 1998.
21. Nakashima H, Aoki M, Miyake T, Kawasaki T, Iwai M, Jo N, Oishi M, Kataoka K, Ohgi S, Ogihara T, Kaneda Y and Morishita R: Inhibition of experimental abdominal aortic aneurysm in the rat by use of oligodeoxynucleotides suppressing activity of nuclear factor κB and ets transcription factors. Circulation 109: 132-138, 2004.
22. Bond M, Baker AH and Newby AC: Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 264: 561-567, 1999.
23. Kim H and Koh G: Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. Biochem Biophys Res Commun 269: 401-405, 2000.
24. Campbell SE, Nasir L, Argyle DJ and Bennett D: Molecular cloning and characterization of canine metalloproteinase-9 gene promoter. Gene 273: 81-87, 2001.
25. da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, Rutledge JC, Vergona R, Sullivan ME and Wang Y: Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 178: 9-17, 2005.
26. Huang W, Alhenc GF and Osborne-Pellegrin MJ: Protection of the arterial internal elastic lamina by inhibition of the renin-angiotensin system in the rat. Circ Res 82: 879-890, 1998,
27. Tomita N, Yamasaki K, Izawa K, Kunugiza Y, Osako MK, Ogihara T and Morishita R: Improvement of organ damage by a non-depressor dose of imidapril in diabetic spontaneously hypertensive rats. Int J Mol Med 19: 571-579, 2007.
28. Tomita N, Morishita R, Lan HY, Yamamoto K, Hashizume M, Notake M, Toyosawa K, Fujitani B, Mu W, Nikolic-Paterson DJ, Atkins RC, Kaneda Y, Higaki J and Ogihara T: In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 11: 1244-1252, 2000.
29. Tomita N, Morishita R, Tomita S, Yamamoto K, Aoki M, Matsushita H, Hayashi S, Higaki J and Ogihara T: Transcription factor decoy for NF-κB inhibits TNF-α-induced IL-6 and ICAM-1 expression in endothelial cells. J Hypertens 16: 993-1000, 1998.
30. Shiraya S, Miwa K, Aoki M, Miyake T, Oishi M, Kataoka K, Ohgi S, Ogihara T, Kaneda Y and Morishita R: Hypertension accelerated experimental abdominal aortic aneurysm through upregulation of nuclear factor-κB and ets. Hypertension 48: 628-636, 2006.
31. Matsumori A, Nunokawa Y and Sasayama S: Nifedipine inhibits activation of transcription factor NF-κB. Life Sci 67: 2655-2661, 2000.
32. Fowkes F, Macintyre C and Ruckley C: Increasing incidence of aortic aneurysms in England and Wales. BMJ 298: 33-35, 1989.
33. Crownenwett JL: Variables that affect expansion rate and rupture of abdominal aortic aneurysms. Ann NY Acad Sci 800: 56-67, 1996.
34. Daugherty A and Cassis L: Angiotensin II and abdominal aortic aneurysms. Curr Hypertens Rep 6: 442-446, 2004.
35. Ihara M, Urata H, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, Ideishi M and Arakawa K: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 33: 1399-1405, 1999.
36. Tsunemi K, Takai S, Nishimoto M, Yuda A, Hasegawa S, Sawada Y, Fukumoto H, Sasaki S and Miyazaki M: Possible roles of angiotensin II-forming enzymes, angiotensin-converting enzyme and chymase-like enzyme, in the human aneurismal aorta. Hypertens Res 25: 817-822, 2002.
37. Hackman DG, Thiruchelvam D and Redelmeier D: Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 368: 659-665, 2006.
38. Lindholt JS, Henneberg EW, Juul S and Fasting H: Impaired results of a randomized double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol 18: 52-57, 1999.
39. The Propranolol Aneurysm Trial Investigators: Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg 35: 72-79, 2002.
40. Wilmink ABM, Hubbard CSFF, Day NE and Quick CRG: Effect of propranolol on the expansion of abdominal aortic aneurysms: a randomized study. Br J Surg 87: 499-500, 2000.
41. Nagashima H, Uto K, Sakomura Y, Aoka Y, Sakuta A, Aomi S, Hagiwara N, Kawana M and Kasanuki H: An angiotensin-converting enzyme inhibitor, not an angiotensin II type I receptor blocker, prevents beta-aminopropionitorile mono-fumarate-induced aortic dissection in rats. J Vasc Surg 36: 818-823, 2002.
42. Chen J, Kuhlencordt PJ, Astern J, Gyurko R and Huang PL: Hypertension does not account for the accelerated atherosclerosis and development of aneurysm in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 104: 2391-2394, 2001.
43. Newman KM, Jean-Claude J, Hong L, Ramey WG and Tilson MD: Cytokines that activate proteolysis are elevated in abdominal aortic aneurysm. Circulation 90: 224-227, 1994.
44. Koch AE, Kunkel SL, Pearce WH, Shah MR, Parikh D, Evanoff HL, Haines GK, Burdick MD and Strieter RM: Enhanced production of chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysm. Am J Pathol 142: 1423-1431, 1993.
45. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N and Baxter BT: Matrix metalloproteinase 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110: 625-632, 2002.
46. Ishibashi M, Egashira K, Zhao Q, Hiasa K, Ohtani K, Ihara Y, Charo IF, Kura S, Tsuzuki T, Takeshita A and Sunagawa K: Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 24: 174-178, 2004.
47. Norman P, Spencer CA, Lawrence-Brown MM and Jamrozik K: C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysm in men. Circulation 110: 862-866, 2004.
48. Vainas T, Lubbers T, Stassen FR, Hemgreen SB, van Dieijen-Visser MP, Bruggeman CA, Kitslaar PJ and Schurink GW: Serum C- reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation 107: 1103-1105, 2003.
49. Tayebjee MH, Nadar S, Blamn AD, Gareth Beevers D, MacFadyen RJ and Lip GY: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 17: 764-769, 2004.
50. Rodringuez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S and Vaziri ND: Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 315: 51-57, 2005.
51. Hayashi M, Yamaji Y, Nakazato Y and Saruta T: The effects of calcium channel blockers on nuclear factor kappa B activation in the mesangium cells. Hypertens Res 23: 521-525, 2000.
52. Roth M, Keul R, Emmons LR, Horl WH and Block LH: Manidipine regulates the transcription of cytokine gene. Proc Natl Acad Sci USA 89: 4071-4075, 1992.
53. Rodler S, Roth M, Nauck M, Tamm M and Block LH: Ca(2+)-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells. J Mol Cell Cardiol 27: 2295-2302, 1995.
54. Walz G, Zanker B, Barth C, Wieder KJ, Clark SC and Storm TB: Transcriptional modulation of human IL-6 gene expression by verapamil. J Immunol 144: 4242-4248, 1990.
55. Sen R and Baltimore D: Multiple factors interact with the immunoglobulin enhancer sequences. Cell 46: 705-716, 1986.
56. Kopp EB and Ghosh S: NF-κB and rel proteins in innate immunity. Adv Immunol 58: 1-27, 1995.